Compare Eli Lilly And Co (LLY) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs UiPath Inc — how do they compare? Eli Lilly And Co trades at $1,176.25 (market cap $1.04T), while UiPath Inc trades at $13.51 (market cap $6.91B). The key difference: Eli Lilly And Co is far larger — about 150.5× UiPath Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while UiPath Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and UiPath Inc for 139 Days on average.
| LLY | PATH | |
|---|---|---|
Market Cap | $1.04T | $6.91B |
Volume | 3,064,878 | 34,321,250 |
Sector | Health | Technology |
52-Week High | $1.28K | $19.29 |
52-Week Low | $799.57 | $9.38 |
Typical Hold Time | 93 Days | 139 Days |
Enterprise Value | $1.09T | $5.70B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
UiPath (PATH) trades at $13.45, up 2.87% today, showing technical bullish momentum despite mixed earnings. The company demonstrates strong revenue growth from $1.43B in 2025 to projected $1.7B in 2026, with net income turning positive at $362M. Recent partnerships with Snowflake and BDO highlight strategic expansion in AI orchestration, while analyst consensus remains cautious with 67% hold ratings.
PATH offers growth potential through AI automation leadership but faces execution risks amid competitive pressures. The stock trades below consensus target of $15.13, suggesting 12% upside if guidance is met. Key risks include pricing pressure and integration challenges with new partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
